Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

Methods are disclosed of treating or preventing hypotension (e.g., neurogenic orthostatic hypotension or postprandial hypotension) or portal hypertension (e.g., bleeding esophageal varices associated with portal hypertension) or ascites (e.g., ascites associated with liver cirrhosis), by oral administration to affected subjects of compositions comprising a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof.

The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.

The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

A food safe, plant based, water soluble, dry powder formulation and an aqueous enteric coating solution made therefrom, that is used for providing an enteric film coating on oral dosage forms including capsules, tablets, and the like; and methods of making the dry powder formulation, making the aqueous coating solution, and coating of oral dosage forms including capsules, tablets, and the like.

Described herein are abuse deterrent oral pharmaceutical compositions, methods for making the same, and methods of treatment using such compositions. In particular, oral pharmaceutical compositions that mitigate the risk of overingestion of one or more active pharmaceutical ingredients are described.

The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride. The kappa opioid receptor agonist may be embedded in an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists and the absorption enhancer of the invention and methods use of these formulations for the prophylaxis and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation; the method comprising administering to the mammal the formulation comprising the kappa opioid receptor agonist and an absorption enhancer.

A method of treating cancer by natural traditional Chinese medicine with sustained release and its preparation method thereof, includes the steps of: administrating a composition of traditional Chinese medicine, wherein the composition contains active ingredients of: ginsenoside, Astragalus polysaccharide, zedoary (Curcuma zedoaria), river bulrush (Sparganium stoloniferum Buch.-Ham), Ternstroemia gymnanthera, Fructus ligustri lucidi, licorice, Chinese skullcap (Scutellaria baicalnsis Georgi), Sculellaria barbata, paclitaxel, Silybum marianum (L.) Gaertn., and Cannabidiol (CBD). The composition can restore body balance and promote self-recovery. The composition can be used as an alternative medicine or can be used in combination with conventional cancer treatment, and is especially target for patients suffered from toxic side effects of radiotherapy and chemotherapy, which can increase the efficiency and reduce the toxicity of conventional cancer treatment and eliminate side effects of vomiting, hair loss, and unbearable soreness of the body.

The present invention belongs to the technical field of nanomedicine, and relates to a method for preparing a therapeutic protein-loaded nanoparticle, as well as a therapeutic protein-loaded nanoparticle, a suspension and a pharmaceutical composition comprising the nanoparticle, and a pharmaceutical preparation comprising the nanoparticle, the suspension or the pharmaceutical composition. The present invention further relates to a use of the nanoparticle in manufacture of a pharmaceutical composition, wherein the pharmaceutical composition is useful in prevention or treatment of a disease that can be prevented or treated by the therapeutic protein comprised in the nanoparticle.